Tag : SPMS

Neurology

End of the Road for High-Dose Biotin in MS?

Newsemia
High-dose biotin, a B vitamin used at lower doses as a food supplement, does not significantly improve disability or walking speed in patients with progressive...
Neurology

High Plasma GFAP Level Predicts Disability in Progressive MS

Newsemia
A high level of glial fibrillary acidic protein (GFAP) in the blood may predict worsening disability in patients with secondary progressive multiple sclerosis (MS), according...
Neurology

Masitinib Impresses in 'Nonactive' Progressive MS

Newsemia
The drug, with a completely new mechanism of action for multiple sclerosis, slowed disability in nonactive primary and secondary progressive forms of the disease, where...
Neurology

NfL Blood Biomarker Captures Suboptimal Treatment Response in MS

Newsemia
Measuring levels of neurofilament light chain is an effective way of detecting disease activity and the need to optimize treatment in patients with multiple sclerosis,...
Neurology

Cardiovascular Risk Factors Linked to Brain Atrophy in MS

Newsemia
Even low levels of exposure to cardiovascular risk factors are important in MS and might affect brain volume loss, a new study suggests. Medscape Medical...
Neurology

FDA OKs Ofatumumab (Kesimpta) for Relapsing Forms of MS

Newsemia
The FDA has approved ofatumumab (Kesimpta) as the first self-administered, targeted B-cell therapy for adults with relapsing forms of multiple sclerosis. FDA Approvals Source link...
Neurology

More Evidence for Neurofilament Light Chain as MS Biomarker

Newsemia
Tracking sNfL levels over time corresponds to multiple sclerosis disease course in a longitudinal study, but use of the blood biomarker for individual prognosis remains...
Neurology

Novel Anti-B-Cell Therapy Looks Promising in MS

Newsemia
A new and novel oral therapy for multiple sclerosis, which inactivates rather than depletes B cells, has shown promising results in its first efficacy study....
Neurology

'Burning Debate' on McDonald Diagnostic Criteria in MS

Newsemia
New McDonald diagnostic criteria for multiple sclerosis were the focus of a debate here at the ECTRIMS 2018 congress that spilled over onto Twitter. Medscape...
Latest News

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

Newsemia
Novartis today announced that both the US Food and Drug Administration and European Medicines Agency have accepted the company’s New Drug Application and Marketing Authorization...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy